Zimmer Biomet Holdings, Inc. (ZBH)

Over the past six months, Zimmer Biomet's stock price experienced a slight decline of 0.69% year-over-year as of October 22, 2025, but showed recent positive momentum with a rise of 0.77% compared to the previous week and 5.97% over the last month. In the second quarter of 2025, Zimmer Biomet reported earnings per share (EPS) of $2.07, surpassing analyst expectations by 4.61%, and demonstrated solid revenue growth of 7.0% year-over-year. The acquisition of Monogram Technologies is expected to fuel growth. The next earnings report is scheduled for November 5, 2025.

Zimmer Biomet's sales are significantly influenced by elective medical procedures, with strong demand for these procedures driving sales growth both domestically and internationally. Demand could be subject to fluctuations related to factors such as patient deductibles, holiday periods, or general healthcare utilization trends for non-emergency surgeries. The company has reported consistent mid-single-digit or better revenue growth for multiple consecutive quarters, indicating a generally stable underlying demand despite potential seasonal variations in elective procedures.

Zimmer Biomet Holdings, Inc. is a global medical technology company focused on musculoskeletal healthcare, operating in the Health Technology sector, specifically in the Medical Specialties and Medical Devices and Instruments industries. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip replacement systems, as well as products for sports medicine, biologics, extremities, trauma, spine, craniomaxillofacial and thoracic areas, office-based technologies, and dental implants. The company aims to provide innovative solutions to restore mobility and alleviate pain for patients.

Zimmer Biomet has a global presence, serving healthcare professionals and patients in over 100 countries. Its operations are divided into three geographical regions: Americas, Europe Middle East and Africa (EMEA), and Asia Pacific. The Americas include the U.S. and other North, Central, and South American markets. The EMEA segment includes key European countries such as France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment covers major markets like Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. Zimmer Biomet maintains approximately 25 production sites globally.

Zimmer Biomet's brand reputation has been positively impacted by the U.S. Food and Drug Administration (FDA) granting Breakthrough Device Designation for its iodine-treated total hip replacement system, marking the first time one of its products has received such a designation. This innovative system also received approval from the Japan Pharmaceutical and Medical Devices Agency (PMDA) in September, highlighting Zimmer Biomet's leadership in advancing musculoskeletal health interventions.

Zimmer Biomet Holdings, Inc. is predominantly owned by institutional investors, with ownership ranging from approximately 80.75% to 97.16% of the company's shares. Major institutional owners include Vanguard Group Inc, Dodge & Cox, BlackRock, Inc., Price T Rowe Associates Inc /md/, State Street Corp, Capital International Investors, and American Century Companies Inc. Insider ownership is relatively low, reported between 0.52% and 1.39%. Tpg Group Holdings Sbs Advisors Inc is a significant individual shareholder, holding 14.70 million shares, representing 7.42% of the company.